UCL Cancer Institute DAC

UCL CI DAC
ci.ega-dac@ucl.ac.uk

Request Access

Dataset ID	Description	Technology	Samples
EGAD00001006133	Bulk RNA-seq for cALL patient-derived PDX samples	NextSeq 500	74
EGAD00001006134	Single cell RNA-seq for PT1-derived PDX samples	NextSeq 500	757
EGAD00001006135	Single cell RNA-seq for primary samples	NextSeq 500	285
EGAD00001006136	Single cell WGS (low pass) for chord blood samples	NextSeq 500	24
EGAD00001006137	Single cell WGS (low pass) for PT1-derived PDX samples	NextSeq 500	539
EGAD00001006138	Single cell WGS (low pass) for primary samples	NextSeq 500	444
EGAD00001009058	We carried out WGS and RNAseq on a cohort of 48 children and young adults with induction failure in T-cell Acute Lymphoblastic Leukemia (T-ALL) to identify genomic drivers of treatment resistance. The study includes WGS for 33 tumour/normal pairs and 15 tumour-only samples. In addition, there is RNAseq data for 37 cases.	Illumina HiSeq 2500 Illumina NovaSeq 6000	118
EGAD00010001872	EPIC methylation arrays on PT1-derived PDXs	EPIC arrays	32
EGAD50000000174	T-ALL relapse usually occurs early but can occur much later, which has been suggested to represent a de novo leukemia. However, we conclusively demonstrate late relapse can evolve from a pre-leukemic subclone harbouring a non-coding mutation that evades initial chemotherapy. Data include 19 WGS samples: - 5 cases with presentation, relapse and remission (germline) samples - 2 cases with presentation and relapse samples, but not remission (germline)	Illumina NovaSeq 6000	19